Skip to main content

Advertisement

Table 1 Treatment effects on mouse energy balance and growth of MCF-7 and MDA-MB231 breast cancer xenografts

From: Leptin-signaling inhibition results in efficient anti-tumor activity in estrogen receptor positive or negative breast cancer

  MCF-7 (estrogen-receptor-positive) xenografts MDA-MB231 (estrogen-receptor-negative) xenografts
  PEG-LPrA2 Sc-PEG PEG-LPrA2 Sc-PEG
Initial food intake (g/day) 2.2 ± 0.7 2.2 ± 0.4 2.6 ± 0.6 2.4 ± 0.2
Final food intake (g/day) 2.9 ± 0.5 2.8 ± 0.4 2.9 ± 0.6 2.9 ± 0.4
Food intake change (g/day) +0.7 +0.6 +0.3 +0.5
Initial body weight (g) 19.7 ± 2.0 19.6 ± 0.7 18.8 ± 0.7 19.2 ± 0.3
Final body weight (g) 23.9 ± 0.7 24.9 ± 1.3 19.3 ± 1.3 20.0 ± 1.4
Body weight change (g) +4.2 +5.3 +0.5 +0.8
Carcass weight (g) 17.1 ± 1.0 17.9 ± 0.7 14.2 ± 1.2* 14.6 ± 0.2*
Final tumor volume (mm3) 20.5 ± 5.0 >1,100 ± 180 210 ± 29 430 ± 45
n 10 10 10 10
  1. Data expressed as mean ± standard deviation (n = 10 tumors/breast cancer type/treatment). *P < 0.05, significant difference in carcass weight of mice hosting MDA-MB-231 breast cancer xenografts treated with pegylated leptin peptide receptor antagonist 2 (PEG-LPrA2) or pegylated scrambled peptide (Sc-PEG) with respect to mice hosting MCF-7 breast cancer xenografts (n = 10 tumors/treatment).